Driving Cell Therapy Innovation: Applying Key Lessons from the Evolution and Commercialization of Protein-Based Therapies

Posted by

What can our experience of traditional bioprocessing teach us about the manufacturing of new cell therapies?

TTP’s Edwin Stone was recently invited to be part of a panel of cell therapy industry experts at the Bioprocess International Conference in Boston.  Bioprocess International has published a transcript here.

edDr Edwin Stone

Edwin is a Life Science Consultant at TTP.  He leads TTP’s cell therapy cost reduction and automation initiative.  He has over 15 years of product development experience and has been responsible for the commercialisation of many disruptive life science products spanning diagnostics, lab analytics and medical devices.  He has a particular interest in enabling new opportunities through the development of complex new technologies and how to successfully realise this in practice.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s